WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis 22 April 2019
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics 21 March 2019
Ochsner Health System and Pfizer partner to develop innovative models for clinical trials 19 February 2019
The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients 08 February 2019
Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations 01 February 2019
Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain 29 January 2019
US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy 14 January 2019
Pfizer initiates phase 2b/3 clinical trial for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with moderate to severe alopecia areata 05 January 2019
Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV™ (bevacizumab) 14 December 2018
Pfizer reaches a global agreement with AbbVie 04 December 2018
Pfizer announces Executive Leadership Team 09 October 2018
Pfizer to award more than $3 million in grants to further breast cancer research 04 October 2018
Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy 05 September 2018
Pfizer and Astellas amend clinical research protocols for two phase 3 trials of enzalutamide in patients with hormone-sensitive prostate cancer 29 August 2018
Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy 16 July 2018
Pfizer to organize for future growth 11 July 2018
Pfizer announces extension of Zithromax® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness 14 June 2018
Pfizer to expand venture investing with $600 million commitment to Pfizer Ventures 06 June 2018
The Pfizer Foundation announces $5 million in grants to support women and families 31 May 2018
Pfizer begins a Phase 1/2 study to evaluate respiratory syncytial virus (RSV) vaccine 22 May 2018
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.